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Abstract
Background: Huntington’s disease is a devastating neurodegenerative condition for which there is no therapy to slow
disease progression. The particular vulnerability of striatal medium spiny neurons to Huntington’s pathology is
hypothesized to result from transcriptional dysregulation within the cAMP and CREB signaling cascades in these neurons.
To test this hypothesis, and a potential therapeutic approach, we investigated whether inhibition of the striatal-specific
cyclic nucleotide phosphodiesterase PDE10A would alleviate neurological deficits and brain pathology in a highly utilized
model system, the R6/2 mouse.
Methodology/Principal Findings: R6/2 mice were treated with the highly selective PDE10A inhibitor TP-10 from 4 weeks of
age until euthanasia. TP-10 treatment significantly reduced and delayed the development of the hind paw clasping
response during tail suspension, deficits in rotarod performance, and decrease in locomotor activity in an open field.
Treatment prolonged time to loss of righting reflex. These effects of PDE10A inhibition on neurological function were
reflected in a significant amelioration in brain pathology, including reduction in striatal and cortical cell loss, the formation
of striatal neuronal intranuclear inclusions, and the degree of microglial activation that occurs in response to the mutant
huntingtin-induced brain damage. Striatal and cortical levels of phosphorylated CREB and BDNF were significantly elevated.
Conclusions/Significance: Our findings provide experimental support for targeting the cAMP and CREB signaling pathways
and more broadly transcriptional dysregulation as a therapeutic approach to Huntington’s disease. It is noteworthy that
PDE10A inhibition in the R6/2 mice reduces striatal pathology, consistent with the localization of the enzyme in medium
spiny neurons, and also cortical pathology and the formation of neuronal nuclear inclusions. These latter findings suggest
that striatal pathology may be a primary driver of these secondary pathological events. More significantly, our studies point
directly to an accessible new therapeutic approach to slow Huntington’s disease progression, namely, PDE10A inhibition.
There is considerable activity throughout the pharmaceutical industry to develop PDE10A inhibitors for the treatment of
basal ganglia disorders. The present results strongly support the investigation of PDE10A inhibitors as a much needed new
treatment approach to Huntington’s disease.
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Introduction
Huntington’s disease (HD) is a devastating neurodegenerative
condition characterized by progressive and severe cognitive,
emotional, and motor dysfunction, and premature death [1].
The disease is caused by expansion of a CAG repeat in exon 1 of
IT15, which encodes for the protein huntingtin [2]. The expanded
n-terminal poly-glutamine tract in mutant huntingtin is the toxic
species [3], with the length of the expansion correlating with age of
onset and, to a lesser extent, disease course [4]. Although
huntingtin is widely expressed, HD is associated with a specific
pattern of neurodegeneration. The striatal medium spiny neurons
are most susceptible and loss of striatal volume is the prominent
pathological finding [5]. However, cortical pathology is also
evident and contributes to the overall dramatic loss of brain
volume (up to 40%) in late stage disease [6]. At present, there are
few options to treat the symptoms of HD and no therapy to slow
the neurodegenerative process.
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mutant huntingtin are under intense investigation but are not fully
understood. Aggregates of mutant huntingtin are found in various
neuronal compartments in autopsy samples of HD brain [7] and
such aggregates are recapitulated in cell culture and transgenic
mouse models [8]. However, the role of these aggregates in the
neurotoxic process is controversial [9]. The effects in experimental
systems of the expression of mutant huntingtin, or a poly-
glutamine n-terminal fragment, are diverse [10]. Findings from
such studies have suggested a number of possible cause/effect
relationships in the neurotoxic process and, importantly, have
formed the basis for developing therapeutic strategies [11]. The
strategy of interest here emerges from evidence that mutant
huntingtin impairs cAMP signaling [12] and gene transcription
mediated by the cAMP response element–binding protein (CREB)
[13,14]. Inhibition of CREB-mediated transcription has been
hypothesized to contribute to neuronal loss in HD [15,16,17,18]
and a decreased transcription of CREB-regulated genes is
observed in HD transgenic animals [16,19,20]. These findings
suggest that counteracting the decreased cAMP signaling and loss
of CREB-regulated transcription may be beneficial in treating
HD.
We first interrogated the above therapeutic strategy by targeting
the cyclic nucleotide phosphodiesterase type IV (PDE4). PDE4
[21] is one of the eleven families of phosphodiesterases that
regulate through metabolic inactivation cyclic nucleotide signaling
throughout the body [22], including in brain [23]. PDE4
inhibition results in activation of cAMP signaling pathways and,
in particular, increases CREB phosphorylation and activation
[24,25]. We have shown that the PDE4 inhibitor rolipram reduces
striatal degeneration in a rat quinolinic acid [26] and in the R6/2
transgenic mouse [27] models of HD. While these results provided
support for targeting cAMP and CREB signaling through PDE
inhibition, they do not provide a direct path to therapy, since
PDE4 inhibitors suffer from severe side effect liabilities that have
precluded successful clinical deployment. Thus, we turned to the
investigation of another phosphodiesterase, PDE10A, as a more
promising target.
PDE10A is highly expressed in the striatal medium spiny
neurons [28,29,30], where it regulates both cAMP and cGMP
signaling cascades [31,32]. Notably, inhibition of PDE10A with
the highly specific inhibitor TP-10 results in robust increase in
cAMP and in CREB phosphorylation in striatum [33]. We have
previously reported that TP-10 treatment reduces loss of striatal
and cortical neurons caused by intrastriatal quinolinic acid
injection in parallel to an increase in striatal and cortical CREB
phosphorylation [34]. Here we report that TP-10 ameliorates the
behavioral and neuropathological sequel of mutant huntingtin
expression in the well-established transgenic mouse model of HD,
the R6/2 mice.
Results
TP-10 drug levels
TP-10 was administered once daily at a dose of 1.5 mg/kg, i.p.
beginning at 4 weeks of age until death. Plasma levels of TP-10,
measured in a satellite group of animals, reach a peak within
approximately 0.5 h after administration (Figure 1). Brain levels
closely tracked the plasma levels and the brain/plasma concen-
tration ratio was 1.3 based on areas under the curve. These
pharmacokinetic parameters are very similar to those reported
previously for TP-10 administered to mice by the subcutaneous
route [33]. Free plasma levels (calculated from the measured total
plasma levels corrected for protein binding) reached a maximum
of 1.9 nM and remained above the IC50 of TP-10 for inhibition of
PDE10A in vitro (0.3 nM) for approximately 4 h (Figure 1). Such
levels of TP-10 are associated with robust increases in striatal levels
of cAMP, cGMP, and CREB phosphorylation and robust efficacy
in mouse behavioral models predictive of antipsychotic efficacy
[33].
Loss of righting reflex and weight
Inhibition of PDE10A increased the age at which R6/2 mice
lost the righting reflex and were euthanized (Figure 2A). The first
R6/2 mouse losing the right reflex was age 76 days. In the R6/2
mice treated with vehicle, 50% of the mice lost the righting reflex
by age 88 days and all animals lost the righting reflex by age 95
days. This time course is similar to that observed by others [3] and
is consistent with our previous results [27]. The time to loss of
righting reflex for R6/2 mice treated with the PDE10A inhibitor
TP-10 was significantly extended (p,0.0001) based on a Kaplan-
Meier analysis. This difference in the Kaplan-Meier survival curve
can best be described by a difference in the rate at which animals
lost the righting reflex. In the vehicle treated group, mice lost the
righting reflex over 76 to 95 days of age. In contrast, more than
75% of the TP-10 treated mice maintained the ability to right
themselves to age 94 days, but then rapidly lost this ability
thereafter and all were euthanized over the next week.
Beginning at approximately 10 weeks of age, R6/2 mice
exhibited significant weight loss and by 14 weeks the vehicle-
treated R6/2 mice were approximately half the size of wild-type
littermates. However, TP-10 treatment did not significantly
modify the weight loss of the R6/2 mice (Figure 2B).
Neurological and behavioral assessments
R6/2 mice exhibit an abnormal hind-limb clasping response
when suspended by the tail [3] that has been associated with the
progression of brain damage [35–37]. PDE10A inhibition slowed
the development of this neurological abnormality. In vehicle-
treated R6/2 mice, the clasping response was evident by 8 weeks
of age and reached near maximal levels by 11 weeks (Figure 2C).
Figure 1. Plasma and brain levels of TP-10 in C57BL/6 mice.
Mice were administered TP-10 at 1.5 mg/kg, i.p. and sacrificed at the
indicated time to obtain samples of plasma and brain for determination
of total TP-10 levels. Plasma levels are presented as ng TP-10/ml and
brain levels are presented as ng TP-10/g tissue wet weight. Each data
point represents the mean from n=3 animals. The horizontal dashed
line is the total plasma level that, when corrected for plasma protein
binding, represents the concentration of TP-10 free in plasma at the IC50
of TP-10 for inhibition of PDE10A in vitro (0.3 nM).
doi:10.1371/journal.pone.0013417.g001
PDE10A Inhibition in R6/2 Mice
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response was not evident until 10 weeks of age and then developed
more gradually. The time spent exhibiting the clasping response
was statistically significantly less in the TP-10 treated mice at
weeks 10–12 (Figure 2C).
Motor coordination was assessed as the ability of mice to
maintain balance on an accelerating rotarod at 6 through 13
weeks of age. The wild type mice were able to maintain balance
for the duration of each test regardless of age and treatment and
TP-10 treatment did not disrupt performance. Because of this
ceiling effect, we exclude the data from the wild type mice from
our parametric statistical analysis, which is focused exclusively on
the two treatment groups of R6/2 mice. As can be seen in
Figure 3A, the R6/2 mice became progressively impaired in motor
coordination. There was no difference between R6/2 treatment
groups during rotarod training and no statistically significant
difference initially. Significantly, TP-10 treatment blunted the
decline in rotarod performance in the R6/2 mice at later time
points. Performance of the vehicle treated R6/2 mice progressed
from a slight impairment at 6 weeks of age to complete loss of the
ability to maintain balance by age 13 weeks. In contrast,
performance deteriorated at a slower rate with TP-10 treatment,
as reflected in significantly longer durations in the R6/2 treated
compared to vehicle treated animals at weeks 11–13. In fact, at 13
weeks, the TP-10 treated R6/2 mice maintained the ability to
balance on the rotarod for an average of 3166 sec.
Locomotor activity in an open field was assessed at ages 5, 7 and
13 weeks. Total distance traveled and speed in the open field were
recorded; however, since the differences between genotypes and
the effect of TP-10 treatment were identical for these two
measures, only the data for distance traveled is presented for
simplicity (Table 1). The initial statistical analysis included
genotype, treatment, and age as main factors in a three way
ANOVA. There was a significant main effect of treatment,
reflective of the fact that TP-10 treatment reduced distance
traveled in the open field in both the wild type and R6/2 mice
(Table 1). This is consistent with previous findings for PDE10A
inhibition on this measure of locomotor/exploratory behavior
[33]. The salient observation in the present study is that PDE10A
inhibition with TP-10 blunted the decline in locomotor activity in
the R6/2 mice as a function of age (Figure 3B). In the vehicle
treated wild type mice, there was only a slight (,14%) decline in
distance traveled from age 5 weeks to age 13 weeks, whereas in the
vehicle treated R6/2 mice, distance traveled declined from the
level at 5 weeks to a greater extent at 7 (,40%) and 13 (,70%)
weeks. With TP-10 treatment, the wild type group evidenced a
small (,10%) increase in distance traveled with increasing age.
Significantly, distance traveled declined only slightly as a function
of age in the R6/2 mice treated with TP-10. In fact, there was only
a 12% decline in the distance traveled between 5 weeks and 13
weeks of age in this group, and the difference in distance traveled
at 13 weeks was only 18% lower in the R6/2 mice as compared to
the wild type mice.
Neuropathological outcome measures
A cohort of R6/2 mice treated with TP-10 or saline, and a
comparison group of wild type mice treated with vehicle, were
sacrificed at 13 weeks of age and brains were processed for analysis
of mutant huntingtin-induced neuropathology.
Expression of mutant huntingtin has pervasive effects on
different aspects of brain morphology. At the grossest level, this
is reflected in an overall reduction in brain volume. The area of
brain most susceptible to mutant huntingtin-induced pathology is
striatum and we examined the effect of PDE10A inhibition on this
Figure 2. Survival, weight, and clasping response in R6/2 mice
treated with TP-10 or vehicle. (A) Kaplan-Meyer analysis of survival.
R6/2 mice treated with TP-10 had a mean survival time that was
significantly (p,0.0001) longer than that of R6/2 mice treated with
vehicle. (B) Weight as a function of age in the wild type and R6/2 mice.
The wild type mice gained weight throughout the course of the study,
whereas the R6/2 mice progressively lost weight. There was no
statistically significant effect of TP-10 treatment in either genotype.
(C) The development of the hind-limb clasping phenotype in R6/2 mice
treated with TP-10 or vehicle. Two way analysis of variance indicated a
statistically significant effect of treatment (F(1,12)=8,86, p,0.0116) and
age (F(6,72)=25,32, p,0.0000). Post hoc analysis indicated that the TP-
10 treated mice showed significantly less clasping at weeks 10, 11, and
12 (*, p,0.01).
doi:10.1371/journal.pone.0013417.g002
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the size of the striatum was markedly reduced in R6/2 mice
compared to wild-type littermates, as illustrated in coronal sections
at representative planes in Figure 4A. The area of striatal tissue in
the step series of coronal sections was first determined. The striatal
area of vehicle treated R6/2 mice (1.460.2610
5 mm
2) was only
27% of that of the wild-type animals (5.260.2610
5 mm
2;
Figure 4B). Treatment of the R6/2 mice with TP10 statistically
significantly reduced by 50% the loss of striatal size
(3.360.2610
5 mm
2; Figure 4B). The total volume of striatum
was reconstructed from the step series of coronal sections,
encompassing the full rostrocaudal extent of the striatum.
Calculated striatal volume of vehicle-treated R6/2 mice
(6.060.1610
5 mm
3) was approximately 70% that of wild type
mice (8.560.1610
5 mm
3; Figure 4C). This atrophy was partially
but significantly ameliorated by treatment of the R6/2 mice with
TP10 (striatal volume of 6.760.1610
5 mm
3; Figure 4C).
Striatal pathology in the R6/2 mice was also reflected in a
reduction in the number of CALB-positive neurons (Figure 5). In
the wild-type mice, the average number of striatal neurons per
mm
2 was 18065, and was statistically significantly reduced to
14164 neurons in the vehicle-treated R6/2 mice (Figure 5A
compared to 5B). PDE10A inhibition nearly completely prevented
the decrease in neuron number, with 17564 NeuN positive
neurons found per field in the TP10-treated R6/2 mice
(Figure 5C). ANOVA indicated that there was a statistically
significant difference in striatal neuron number. Post hoc analyses
indicated that the vehicle-treated R6/2 mice had a significantly
lower number of striatal neurons than did either the wild type mice
or the TP-10 treated R6/2 mice; the latter two groups did not
differ (Figure 5D).
A more detailed examination of the effect of TP-10 treatment
was carried out in sections stained for calbindin 28K (CALB),
which is a striatal- specific marker of the medium spiny neurons.
Visual observation revealed that the CALB-positive neurons of
vehicle treated R6/2 mice exhibited a previously described
shrunken appearance [3] and were of apparently smaller size
than in wild-type mice. Quantitative analysis using confocal
microscopy confirmed that the average area of CALB positive
neurons in the R6/2 mice (77.261.1 mm
2) was indeed statistically
significantly smaller than in wild-type mice (99.961.3 mm
2;
Figure 5E). Treatment of the R6/2 mice with TP-10 almost
completely ameliorated this change in striatal neuron appearance
and size (94.861.2 mm
2; Figure 5E).
The expression of exon 1 of mutant huntingtin in the R6/2
mice results in the formation of neuronal intranuclear inclusions
(NIIs), detected with the antibody EM-48 [40]. EM-48 immuno-
reactivity was abundant in striatum from the vehicle-treated R6/2
mice (Figure 6). In fact, 42868 NIIs/mm
2 were observed in these
animals (Figure 6 B). The average number of NIIs was significantly
reduced by 25% to 33065 NIIs/mm
2 in mice treated with TP-10
Figure 3. The effect of TP-10 treatment on motor behaviors. (A)
Latency to fall from the accelerating rotarod in the R6/2 mice. A two
way ANOVA indicated an overall significant effect of treatment
(F(1,16)=398,54; p,0.0000) and age (F(7,112)=149,16; p,0. 0000)
and a age X treatment interaction (F(7,112)=27,4; p,0.0000). R6/2 mice
treated with vehicle exhibited a progressive decrease in the latency to
fall and this decrease was blunted by TP-10 treatment. Specifically, the
TP-10 treated groups had a significantly longer latency to fall compared
to the vehicle treated group at weeks 10–12 of age (*, p,0.0002). (B)
Distance traveled in the open field at ages 5, 7 and 13 weeks. Total
distance traveled during a 10 min test session is expressed as a
percentage of the distance traveled at 5 weeks for each group (see
Table 1 for data from which these percentages were calculated). Wild
type mice treated with vehicle exhibited only a slight decrease in
distance traveled over the repeated exposures to the open field. In
contrast R6/2 mice treated with vehicle exhibited a progressive
decrease in distance traveled. This difference between wild type and
R6/2 mice was largely ameliorated by TP-10 treatment. The TP-10
treated R6/2 mice had a lesser decrease in distance traveled with
repeated testing, as compared to the vehicle treated R6/2 mice. There
was a trend for the TP-10 treated wild type mice to travel a slightly
greater distance over repeated testing.
doi:10.1371/journal.pone.0013417.g003
Table 1. Distance traveled in an open field.
Vehicle TP-10
WT R6/2 WT R6/2
5 weeks 55626252 48326217 33706184 30556137
7 weeks 57206172 28636183 35496163 2790628
13 weeks 46506121 13496218 37286225 26896144
Groups of wild type (WT) or R6/2 mice treated with vehicle or TP-10 were
placed in a circular open field at ages 5, 7, and 13 weeks and the total distance
traveled (cm) over 10 min was recorded. Each value is the mean 6 S.E.M. The
statistical analysis indicated an overall significant effect of genotype
(F(1,59)=42,20;P,0,0000) and treatment effect (F(1,59)=22,74; P,0,0000) and
a genotype X treatment interaction (F(1,59)=20,78; P,0,000) and lastly a
treatment X age interaction (F (2,59)=8,04; P,0,0008. Post hoc analysis
indicated that wild type mice traveled a significantly greater distance than the
R6/2 mice (P,0,0004). R6/2 mice treated with TP-10 traversed a significantly
greater distance than did vehicle treated R6/2 mice (P,0.017). These data,
expressed as a percentage distance traveled at week 5, are also presented in
Figure 3.
doi:10.1371/journal.pone.0013417.t001
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Figure 6A).
The striatal neuron damage caused by expression of mutant
huntingtin induces the activation of microglia (Figure 7). In wild-
type mice, only scattered microglia were visualized by CD-11
immunostaining (Figure 7A). These had the ovoid body and lack
of cellular processes characteristic of the quiescent state. In
contrast, an intense microglial reaction was evident in the vehicle
treated R6/2 group, where microglial cells appeared numerous,
had rod-shaped cell bodies with coarse arborizations (Figure 7B).
This microglial reaction was attenuated in TP-10 treated R6/2
mice, with fewer reactive cells evident among the normal quiescent
cells (Figure 7C).
Expression of mutant huntingtin in the R6/2 mice also results in
cortical pathology (Figure 8). The number of NeuN positive
neurons per mm
2 was significantly lower in vehicle treated R6/2
mice (16063) compared to wild type mice (18167; Figure 8B vs.
8A). PDE10A inhibition partially ameliorated this loss of cortical
neurons (Figure 8C). The number of NeuN positive neurons was
statistically significantly higher in the TP-10 treated R6/2 mice
(16964) than in vehicle treated R6/2 mice, and was not
statistically different from that in the wildtype mice (Figure 8D).
Figure 4. Effects of TP-10 treatment on striatal atrophy in R6/2 mice at 13 weeks of age. (A) Transmitted light microscope images showing
representative Nissl-stained coronal sections of a wild-type mouse, a vehicle treated R6/2 mouse and a TP10-treated R6/2 mouse, (left to right,
respectively). Marked gross atrophy and enlarged lateral ventricles are present in the sections from the vehicle treated R6/2 mouse compared the
wild type mouse. These differences are largely absence from the sections of the R6/2 mouse treated with TP-10 from 4 to 13 weeks of age. (B)
Quantification of differences in striatal area. Striatal area was calculated (see Methods) from sections taken from wild type and vehicle- or TP-10
treated R6/2 mice (n=6/group). An one-ANOVA indicated an overall significant effect of group (F (2,24)=62.66; p,0.0000). Post hoc analysis
indicated that R6/2 mice treated with vehicle had a significantly reduced striatal area compared to the wild type group. The striatal area of R6/2 mice
treated with TP-10 was significantly greater than that of the vehicle treated R6/2 mice (p,0.00014), yet significantly smaller than that of the wild type
mice (p,0.00013). (C) Quantification of differences in striatal volume in the same groups as (B). An ANOVA indicated an overall significant effect of
group (F (2,5)=7,14; p,0.03). Post hoc analysis indicated that R6/2 mice treated with vehicle had a significantly reduced striatal volume compared to
the wild type group. The striatal volume of R6/2 animals treated with TP-10 was intermediate between these two groups, and was significantly
greater than that of the vehicle treated R6/2 mice (p,0.03), yet significantly smaller than that of the wildtype mice (p,0.03).
doi:10.1371/journal.pone.0013417.g004
PDE10A Inhibition in R6/2 Mice
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13417Immunohistochemical analysis of pCREB and BDNF
PDE10A regulates cAMP signaling and activation of the
transcription factor CREB in striatum [33]. Deficiency in these
signaling cascades is hypothesized to contribute to the pathology
caused by mutant huntingtin in mice and in HD patients. One of the
key downstream mediators in this regard is BDNF, a principal
neurotrophicfactorforbothstriatalandcorticalneurons.Thus,itwas
of interest to investigate the effects of PDE10A inhibition on CREB
phosphorylation (pCREB) and BDNF in the R6/2 model used here.
Striatal medium spiny neurons were labeled with antibodies to
CALB and the intensity of pCREB or BDNF immunoreactivity
associated with the surviving CALB-positive neurons was
quantified (Figure 9). The intensity of pCREB labeling was
statistically significantly lower in the neurons of the vehicle treated
R6/2 mice (28.260.6 arbitrary units) compared to the wild-type
littermates (39.060.5; Figure 9B vs. 9A, 10G). This difference was
ameliorated by PDE10A inhibition, with pCREB levels in TP10-
treated R6/2 mice (37.060.9) restored to the same level as in the
wild-type mice (Figure 9C, 9G). The level of BDNF immunore-
activity associated with the striatal medium spiny neurons was also
reduced in vehicle-treated R6/2 mice (17.160.3) compared to
wild-type mice (22.860.3; Figure 9D vs 9E). TP-10 treatment of
the R6/2 mice resulted in statistically significantly higher levels of
BDNF (20.160.3) compared to vehicle treated R6/2 mice, an
increase of 40% (Figure 9F, 9H).
In NeuN-positive cortical neurons, the levels of both pCREB
and BDNF were statistically significantly reduced in vehicle
treated R6/2 mice (4060.3 vs. 3460.4 arbitrary units, respec-
tively) compared to wild-type mice (5560.6 and 6460.5;
Figure 10). TP-10 treatment of the R6/2 mice partially but
statistically significantly ameliorated these decreases. Specifically,
pCREB levels were 40% higher (4660.3) and BDNF levels were
30% higher (4560.3) in the TP-10 treated compared to vehicle
treated R6/2 mice.
Discussion
The CAG expansion in the protein huntingtin that causes HD is
selectively detrimental to striatal medium spiny neurons and
cortical pyramidal neurons, despite a much broader expression
[5,6]. Studies in experimental systems and findings from post
mortem brain tissue from HD patients have revealed a number of
effects of mutant huntingtin that may underlie this neurotoxicity
[10,11]. However, it is not clear which of these effects are causal or
that account for the selective vulnerability of cortical and striatal
neurons. It is also unresolved as to how toxicity in one of these
susceptible neuronal populations impacts the vulnerability of the
other. Here we report that pharmacological inhibition of the
striatal specific phosphodiesterase, PDE10A, ameliorates both
striatal and cortical neuropathology in the R6/2 mice. These
Figure 5. Effects of TP-10 treatment on striatal neuron number and volume in R6/2 mice. Representative photomicrographs of DAB
immunohistochemistry for the marker of the medium spiny neurons, calbindin-28K (CALB, black), in the striatum of a (A) wild-type mouse, (B) vehicle
treated R6/2 mouse, and (C) R6/2 mouse treated with TP10 from 4 to 13 weeks of age. There is a marked decrease in neuronal count in the sample
from a vehicle treated R6/2 mice compared to wild-type mice and TP10 treated R6/2 mice. (D) Quantification of the number of striatal neurons
labeled with CALB. Striatal neuron counts were carried out (see Methods) on sections from wild type and vehicle- or TP-10-treated R6/2 mice (n=6/
group). An ANOVA indicated an overall significant effect of group (F(2,90)=36,48; p,0.0000). Post hoc analysis indicated that R6/2 mice treated with
vehicle had a significantly reduced density of CALB-positive neurons in striatum compared to the wild type group. The density of striatal neurons in
R6/2 mice treated with TP-10 was not statistically different to that of wild type mice, and was significantly greater than that of the vehicle treated R6/
2 animals (p,0.0001). (E) Area of striatal neuron cell bodies labeled with CALB. Cell body area of approximately 400 neurons per animal (n=6/group)
was measured using Zeiss LSM software. An ANOVA indicated an overall significant effect of group (F(2,899)=61,64; p,0.0000). Post hoc analysis
indicated that R6/2 mice treated with vehicle had a significantly reduction in the size of striatal neurons compared to wild type animals (p,0.00002).
The size of striatal neurons in R6/2 animals treated with TP-10 was not statistically different to that in wild type animals, and was significantly greater
than that of the vehicle treated R6/2 animals (p,0.00002).
doi:10.1371/journal.pone.0013417.g005
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also support the use of PDE10A inhibitors as a new therapeutic
approach to HD. This is particularly significant since a number of
such compounds are in clinical development. These points are
elaborated below.
PDE10A is one of the superfamily of phosphodiesterases that
regulate through metabolic inactivation cyclic nucleotide signaling
throughout the body. PDE10A is expressed at high levels in striatal
medium spiny neurons, where it is distributed throughout the
soma, dendritic, and axonal compartments [28–30]. PDE10A
mRNA is also detected broadly throughout the brain, including in
cortex [29]. However, mRNA levels are 20-fold or more lower
than in striatum, and only very low levels of PDE10A-like
immunoreactivity, confined to the nuclear/perinuclear region, are
detected with one antibody [28,29] but not a second [41]. Acute
pharmacological inhibition of PDE10A results in a robust increase
in cAMP and cGMP levels in striatum in wild-type mice and rats
[31,33]. In mice, the PDE10A inhibitor-induced increase in cAMP
Figure 6. Effects of TP-10 treatment on the density of NIIs in the striatum of R6/2 mice. Representative photomicrographs of DAB
immunohistochemistry for EM48 (black), which labels neuronal intranuclear inclusions containing aggregated mutant huntingtin (NIIs) in the striatum
of a (A) wild type, (B) vehicle treated R6/2, or (C) R6/2 mouse treated with TP10 from 4 to 13 weeks of age. (D) Quatification of NIIs in vehicle- or TP-
10 treated R6/2 mice (see methods, n=6/group). There were no NIIs detected in striatum of wild type mice, so this group was not included in the
statistical analysis. A t-test indicated that the density of NIIs in striatum of R6/2 mice treated with TP-10 was lower than that in R6/2 mice treated with
vehicle (p,0.0001).
doi:10.1371/journal.pone.0013417.g006
Figure 7. Effects of TP-10 treatment on reactive microglia in the striatum of R6/2 mice. Representative photomicrographs of DAB
immunohistochemistry for the marker of activated microglia, CD11b (black), in the striatum of a (A) wild type, (B) vehicle treated R6/2, or (C) R6/2
mouse treated with TP10 from 4 to 13 weeks of age. In the sample from the vehicle treated R6/2 mouse, there is an apparent intense microglial
reaction, in which microglial cells appear numerous and with coarse arborizations and a rod-shaped body. In the sample from a TP-10 treated R6/2
mouse, there are fewer reactive cells, along with quiescent cells.
doi:10.1371/journal.pone.0013417.g007
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well as the induction of striatal of cfos and neuropeptide mRNA
expression [42,43]. In contrast, there are no detectable changes in
any of these biochemical markers in non-striatal tissues [33,43].
These results indicate that the most significant, if not exclusive,
effect of PDE10A inhibition is on cyclic nucleotide signaling in
striatal medium spiny neurons.
In the present study, we found that PDE10A inhibition had a
significant effect on the development of neurological deficits in the
R6/2 mouse, a model of HD [3]. The R6/2 mice express the first
exon of the huntingtin gene engineered to contain ,150 CAG
repeats. Beginning at ,8 weeks of life these mice develop a
number of behavioral and neuropathological sequelae mirroring
pathologies observed in HD patients. Life span is significantly
shortened to 12 to 15 weeks [3,27], with differences in life span
observed between laboratories accounted for, at least in part, by
differences in animal husbandry. We administered to R6/2 mice
the PDE10A inhibitor, TP-10, beginning at 4 weeks of age, before
the development of neurological impairment, until the time of
euthanasia. We found that PDE10A inhibition significantly
delayed the induction of in-life neurological impairment. TP-10
treatment slowed the development of the hind-limb clasping reflex,
a neurological abnormality that tracks disease progression [3,35–
37], and also reduced deficits in rotarod performance and in open
field activity. The age at which R6/2 mice lost the righting reflex
and were euthanized was significantly extended by treatment with
the PDE10A inhibitor TP-10, based on a Kaplan-Meier analysis.
This difference in the Kaplan-Meier curve is best described as a
difference in the rate at which the treatment groups lost the
righting reflex. Specifically, ,75% of the TP-10 treated R6/2
mice maintained the ability to right for 13 weeks, after which the
animals were rapidly lost. In contrast, animals were lost from the
vehicle treated group at a gradual rate beginning at 11 weeks. It is
interesting to note that TP-10 treatment did not alter the
significant weight loss observed in the R6/2 mice. We speculate
that the rapid decline of the TP-10 treated mice at week 14 of age
may have been due to this feature of the phenotype that
overwhelmed the beneficial effects on neurological function.
Corresponding to these in-life effects, PDE10A inhibition
ameliorated neuropathology in the R6/2 mice. TP-10 treatment
reduced by 50% the loss of striatal area and nearly completely
ameliorated the loss of and morphological changes in the medium
spiny neurons, including the quantitative reduction in soma size.
Medium spiny neurons in the R6/2 mice accumulate NIIs
comprised of aggregates of the poly-glutamine peptide encoded by
the huntingtin exon 1 transgene [8]. TP-10 treatment significantly
Figure 8. Effects of TP-10 treatment on the density of cortical neurons in R6/2 mice. Representative photomicrographs of single label
immunofluorescence for the neuronal marker NeuN (red) to label cortical neurons in samples taken from a (A) wild-type, (B) a vehicle treated R6/2, or
(C) R6/2 mouse treated with TP10 from 4 to 13 weeks of age. There is a marked decrease in neuronal count in the sample from a saline treated R6/2
mice compared to wild-type mice and TP10 treated R6/2 mice. (D) Quantification of the number of cortical neurons labeled with NeuN. Cortical
neuron counts were carried out (see Methods) on sections from wild type and vehicle- or TP-10-treated R6/2 mice (n=6/group). An ANOVA indicated
an overall significant effect of group (F(2,39)=3,61; p,0.03). Post hoc analysis indicated that R6/2 mice treated with vehicle had a significantly
reduced density of NeuN-positive neurons in cortex compared to the wild type group (p,0.04). The density of cortical neurons in R6/2 animals
treated with TP-10 was intermediate between these two groups, and was significantly greater than that of the vehicle treated R6/2 mice (p,0.04), yet
significantly smaller than that of the wild type mice (p,0.04).
doi:10.1371/journal.pone.0013417.g008
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inhibition also had a significant beneficial effect on cortical
pathology in the R6/2 mice. TP-10 treatment decreased the
reduction in cortical neuron counts by 40%. Finally, TP-10
treatment was accompanied by a significant increase in phos-
phorylated CREB and BDNF in both striatum and cortex.
The beneficial effects of PDE10A inhibition on striatal
pathology are readily rationalized. PDE10A is expressed at high
levels in medium spiny neurons and inhibiting the enzyme results
in a robust increase in striatal cAMP levels and activation of
cAMP-mediated signaling pathways [31,33,42]. The increase in
medium spiny neuron cAMP signaling that results from PDE10A
Figure 9. Effects of TP-10 treatment on pCREB and BDNF in the striatum of R6/2 mice. Representative confocal laser scanning microscopy
images of dual-label immunofluorescence for CALB (red) and pCREB (green, panels A–C) or BDNF (green, panels D–E) in striatal samples from a (A,
D) wild-type, (B, E) vehicle treated R6/2, or (C, F) R6/2 mouse treated with TP-10 from 4 to 13 weeks of age. For both pCREB and BDNF, there is a
reduced density of immunoreactivity in the R6/2 vehicle treated samples relative to the wild type samples. This decrease is largely eliminated in
samples from R6/2 mice treated with TP-10. (G) Quantification of the intensity of pCREB immunoreactivity associated with CALB-labeled striatal
neurons. The intensity of pCREB immunoreactivity associated with CALB-positive cells were carried out (see Methods) on sections from wild type or
R6/2 mice treated with vehicle or TP-10 (n=6/group). A two way ANOVA indicated an overall significant effect of genotype (F(1,1008)=103,76;
p,0.0000) and treatment (F(1,1008)=50,59; p,0.0000) and a genotype X treatment interaction (F(1,1008)=50,59; p,0.0000). Post hoc analysis
indicated that there was no statistically significant difference in pCREB level in wild type mice treated with TP-10 or vehicle. R6/2 mice treated with
vehicle had a significantly reduced pCREB level compared to the vehicle treated wild type group (p,0.00002). The pCREB level in R6/2 animals
treated with TP-10 was not statistically different to that in the wild type groups, and was significantly greater than that of the vehicle treated R6/2
animals (p,0.0000). (H) Quantification of the intensity of BDNF immunoreactivity associated with CALB-labeled striatal neurons. A two way ANOVA
indicated an overall significant effect of genotype (F(1,1270)=130.23; p,0.0000) and treatment (F(1,1270)=15.63; p,0.0001) and a genotype X
treatment interaction (F(1,1270)=15.63; p,0.0001). Post hoc analysis indicated that there was no statistically significant difference in BDNF level wild
type mice treated with TP-10 or vehicle. R6/2 mice treated with vehicle had a significantly reduced BDNF level compared to the vehicle treated wild
type group (p,0.00002). The BDNF level of R6/2 animals treated with TP-10 was not statistically different to that in the wild type groups, and was
significantly greater than that of the vehicle treated R6/2 animals (p,0.0000).
doi:10.1371/journal.pone.0013417.g009
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downstream mechanisms [12]. PDE10A inhibition may also
ameliorate HD-specific deficits in cAMP signaling, as proposed
to occur based on findings in HD models [12] and as evidenced by
decreased levels of cAMP in cerebrospinal fluid sampled from HD
patients [44]. One of the deficits in cAMP regulated-signaling that
has been hypothesized to be specifically involved in the
development of HD pathology is reduced transcription mediated
by the transcription factor CREB [13–20]. PDE10A inhibition in
normal mouse brain produces a robust increase in CREB
activation downstream of cAMP [31,33] as well as an increase
in transcription of cfos and striatal neuropeptide genes [42,43].
Furthermore, we observe here a significant increase in phosphor-
ylated CREB in brain of R6/2 mice treated with TP-10. It has also
been suggested that a causal factor in MSN pathology in HD stems
from deficient trophic support due to a decrease in striatal BDNF
[45,46,47]. We observed a significant increase in BDNF levels in
striatum of R6/2 mice with TP-10 treatment. Thus, PDE10A
inhibition-induced increases in striatal cAMP signaling, CREB
mediate transcription, and BDNF levels all may contribute to the
significant amelioration of striatal pathology resulting from
treatment of the R6/2 mice with the PDE10A inhibitor TP-10.
The mechanism(s) whereby PDE10A inhibition increases
striatal, and cortical, BDNF levels, and ameliorates cortical
pathology are more speculative. BDNF is delivered to striatum
by anterograde transport from cortical and, to a lesser extent,
midbrain striatal inputs [48]. However, retrograde transport of
BDNF from striatum back to cortex is also proposed as a
significant element of trophic support to the source cortical
neurons [48]. We suggest that the amelioration of striatal
pathology by PDE10A inhibition may maintain corticostriatal
synaptic interconnectivity, with the secondary effect of maintain-
ing retrograde transport of BDNF to cortex. This, in turn, may
reduce cortical neuron pathology. However, it is also possible that
there is a direct effect of TP-10 treatment on cortical CREB
phosphorylation and BDNF synthesis resulting from inhibition of
the nuclear/perinuclear PDE10A present in cortex, although there
is no evidence for similar effects in non-diseased rodent brain [43].
Nonetheless, given that this is an important mechanistic question,
further investigation is warranted. Insight may be garnered from
an analysis of the promoter driving the increase in cortical BDNF
levels following PDE10A inhibitor treatment [48]. A preferential
increase driven from the CREB-regulated exon III promoter may
suggest a direct effect of PDE10A inhibition on cortical neurons.
A notable finding is that PDE10A inhibition reduced the
number of NIIs. In this respect, PDE10A inhibition is similar to
overexpression of BNDF, in that both treatments reduce both
neuropathology and NII accumulation [47]. The role of NIIs in
the pathology of HD is controversial [9] and it has yet to be
resolved whether these protein aggregates are causal for pathology
or are protective by providing a sink to reduce the concentration of
soluble toxic mutant huntingtin products. The latter hypothesis is
based on finding that some treatments that reduce neuronal
pathology are accompanied by an increase in NIIs. The effects of
PDE10A inhibition and BDNF overexpression suggest that the
formation of NIIs is, at least in part, driven by the underlying
neuropathology.
The present results strongly support the targeting of deficient
cAMP signaling as a therapeutic strategy to slow disease
progression in HD. Given that PDE10A inhibition may affect
cAMP signaling exclusively in medium spiny neurons, the present
findings provide insight into the interrelationship of striatal and
cortical pathology in the disease and indicate that targeting striatal
pathology may have a broader impact. Finally, the observation
that NII accumulation was reduced by PDE10A inhibition
suggests that the formation of these aggregates may be driven by
more fundamental pathological processes. We note that these
conclusions must be limited at present in that only the R6/2
Figure 10. Effect of TP-10 treatment on pCREB and BDNF levels in cortex of R6/2 mice. (A) Quantification of the intensity of pCREB
immunoreactivity associated with NeuN-labeled cortical neurons at age 13 weeks. The intensity of pCREB immunoreactivity associated with NeuN-
positive cells were carried out (see Methods) on sections from wild type or R6/2 mice treated with vehicle or TP-10 from 4 to 13 weeks of age (n=6/
group). A two way ANOVA indicated an overall significant effect of genotype (F(1,1558)=868.66; p,0.000) and treatment (F(1,1558)=45.46;
p,0.0000) and a genotype X treatment interaction (F(1,1558)=45.46; p,0.0000). Post hoc analysis indicated that there was no statistically significant
difference in pCREB level in wild type mice treated with TP-10 or vehicle. R6/2 mice treated with vehicle had a significantly reduced pCREB level
compared to the vehicle treated wild type group. The pCREB level in R6/2 animals treated with TP-10 was not statistically different to that in the wild
type groups, and was significantly greater than that of the vehicle treated R6/2 animals (p,0.000). (B) Intensity of BDNF immunoreactivity associated
with NeuN-labeled cortical neurons. A two way ANOVA indicated an overall significant effect of groups (F(1,1148)=540.66; p,0.000) and treatment
(F(1,1148)=52.13; p,0.0000) and a genotype X treatment interaction (F(1,1148)=52.69; p,0.000). Post hoc analysis indicated that there was no
statistically significant difference in BDNF level wild type mice treated with TP-10 or vehicle. R6/2 mice treated with vehicle had a significantly
reduced BDNF level compared to the vehicle treated wild type group. The BDNF level of R6/2 animals treated with TP-10 was statistically different to
that in the wild type groups, and was significantly greater than that of the vehicle treated R6/2 animals (p,0.000008).
doi:10.1371/journal.pone.0013417.g010
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behavioral assays and assessments of pathology were possible. It
will be of considerable interest to investigate whether similar
beneficial effects of PDE10A inhibition are observed in other
preclinical models of Huntington’s disease using a broader range
of analytical techniques.
Perhaps the greatest significance of the present findings in the
mouse model of HD is strong support for the investigation of
PDE10A inhibitors as a treatment for the human disease. There
is significant progress in the clinical development of PDE10A
inhibitors, with a number of pharmaceutical discovery programs
underway [49,50] and with PF-2,545,920 (also referred to as MP-
10 [Ref 33], a very close structural analog of TP-10) having
advanced to Phase II testing [51]. The primary therapeutic
indication for PF-2,545,920 is the treatment of schizophrenia. It
is noteworthy that HD patients often suffer severe neuropsychi-
atric symptoms that share commonality with those suffered by
patients with schizophrenia. The pathophysiology underlying
these symptoms may similarly stem from striatal dysfunction.
Thus, it is reasonable to speculate that PDE10A inhibitors may
have a symptomatic benefit against the neuropsychiatric
symptoms of HD. These neuropsychiatric symptoms often
develop well before a formal diagnosis of HD, which is based
on the occurrence of chorea. Thus, PDE10A inhibitors may offer
HD patients early symptom relief, with long term therapy slowing
disease progression.
Methods
Ethics Statement
All studies were conducted in accordance with European
Communities Council Directive of 24 November 1986 (86/609/
EEC) and approved by the Santa Lucia Foundation Animal Care
and Use committee (protocol #45/08).
Animals and treatments
Breeding pairs of mice to generate the R6/2 animals used in this
study were obtained in 2009 from Jackson Laboratories (Bar
Harbor, ME, stock number 002810). The colony was expanded by
breeding Ovarian Transplanted hemizygote females X
B6CBAF1/J males as recommended by Jackson Laboratories.
The F1 mice used for experiments were genotyped by PCR assay
of DNA obtained from tail tissue. The CAG repeat number is
reported by Jackson Laboratories as 160+/2 10, but was not
independently confirmed. Mice were identified by a randomly
assigned code so that the studies were performed blind as to the
genetic identity. Mice were handled under the same conditions by
one investigator at the same time of day. All the behavioral and
histological data were collected by observers who were blinded to
treatment. The mice were housed five in each cage under standard
conditions with ad libitum access to food and water. The number
of animals used for each study is indicated in Table 2.
Treatments beginning at 4 weeks of age included: R6/2 mice
administered TP-10 (1.5 mg/kg once per day) dissolved in saline
containing 0.5% DMSO, and 0.5% Emulfor
TM (Fluka, New York,
NY); R6/2 mice administered vehicle only (1 ml/kg once per day),
and wild type mice given TP-10 or vehicle. Treatments were by
intraperitoneal (i.p.) injection with solutions prepared freshly daily.
TP-10 was synthesized at Pfizer Inc. (Groton, CT).
TP-10 levels in plasma and brain at different time points after
i.p. administration were determined in a separate group of
C57BL/6 mice (n=3 per time point). Analytical methods were as
previously described [33].
Loss of righting reflex and weight
Animals were weighed daily starting at the beginning of
treatment and the average of weekly weight was calculated. The
criterion for euthanasia was loss of righting reflex (30 s cutoff),
according to Stack and co-workers [10].
Assessment of neurological and behavioral function
All behavioral testing was conducted at least 6 h after daily
treatment.
Mice of the R6/2 strain exhibit a hind-limb clasping phenotype
when suspended by the tail [3]. The clasping phenotype has
previously been used to study the disease progression in transgenic
HD mice [35,36] where it is considered a measure of neurological
impairment [37]. Mice were suspended by their tail for 180
seconds. The total amount of time spent clasping the hind limb
was recorded daily and the average duration over each week was
calculated.
Motor coordination and balance was assessed using a five-
station mouse rotarod apparatus (Rotarod/RS LSI Letica,
Biological Instruments, Varese, Italy). In each station, the rod
was 6 cm in length and 3 cm in diameter. Mice were trained at 5
weeks of age to maintain balance with increasing speed up to a
constant speed of 16 rpm for three consecutive trials. The test
sessions were conducted by one rotarod trial administered twice a
week from 6 to 13 weeks. In this session, the speed of rotation was
increased from 4 to 16 rpm over 60 s. Mice were given 3 trials on
the rod, and the latencies to fall were measured and averaged. For
the mice that did not fall, a maximum latency of 60 s was assigned.
Motor activity was measured in an open field consisting of a
circular arena (60 cm diameter) with the floor painted white and
divided into central and peripheral sectors by drawn black lines.
The total area of the two sectors was similar (approximately
1400 cm
2). The apparatus was contained in a soundproof room
illuminated by a red ceiling light (80 W). A video camera above
the arena was connected to a video recorder and to a monitor
located in an adjacent room. Mice were placed in the arena for 10
Table 2. Number of animals.
Genotype Treatment Behavior and Survival Neuropathology pCREB and BDNF
WT Vehicle 24 6 6
WT TP10 24 6 6
R6/2 vehicle 20 6 6
R6/2 TP10 21 6 6
The number of animals used for the different endpoints examined.
doi:10.1371/journal.pone.0013417.t002
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arena was recorded by means of dedicated software (Noldus
Information Technologies, Wageningen, the Netherlands). The
data were collected when the mice were pre-symptomatic
(5weeks), early symptomatic (7weeks) and fully symptomatic
(13weeks).
Neuropathological assessment
A cohort of 13 week old R6/2 mice treated with TP-10 or
vehicle, and a corresponding cohort of wild type mice treated with
vehicle were sacrificed and brains processed for neuropathological
assessments.
Tissue processing
Animals at 12 weeks of age were deeply anesthetized and then
transcardially perfused with saline solution containing 0.01 ml
heparin, followed by 60 ml of 4% paraformaldehyde in saline
solution. The brains were removed and postfixed overnight at 4uC
in 4% paraformaldehyde in saline solution. Brains were then
immersed in a cryoprotection solution of 10% sucrose and 20%
glycerol in 0.1 M phosphate buffer (PB) with sodium azide 0.02%
for 48 h at 4uC. Brains were frozen and then serially sectioned on
a sliding microtome at 40 mm thickness. Sections were mounted
on gelatin-coated slides and coverslipped with GEL-MOUNT
TM.
Sections were examined using an epi-illumination fluorescence
microscope (Zeiss Axioskop 2). A confocal laser scanning
microscopy (Zeiss LSM 510) was subsequently used to acquire
all the images for quantification. Controls for specificity of
immunohistochemical labeling included omission of the primary
antibody and use of preimmune normal mouse and rabbit serum
as previously described [26,52–54].
Evaluation of striatal area and volume
Standard Nissl staining was employed on coronal step serial
sections from rostral neostriatum through the level of anterior
commissure (interaural 4.66 mm/bregma 0.86 mm to interaural
3.34 mm/bregma 20.46 mm) from brains of 4 animals per group.
The striatal area was traced in each section and the striatal area
was measured using Neurolucida Stereo Investigator software
(Microbrightfield, Cochester, VT, USA). The total volume of the
striatum was calculated from these area measurements using the
same software.
Number of surviving striatal neurons
Sections were stained with an antibody against the neuron-
specific nuclear antigen NeuN (MAB377X, Chemicon, Temecula,
CA). Immunoreactivity was visualized using the diaminobenzidine
(DAB)–immunoperoxidase technique as previously described [52].
Cells exhibiting a nuclear DAB signal were counted in each of
three 1.0-mm-square confocal microscope fields, in each of three
spaced coronal sections through the neostriatum in both
hemispheres of 6 mice from each treatment group. The average
density of straiatal neurons per mm
2 in each animal, and then in
each group was calculated.
Striatal neuron area
Sections were stained with an antibody against Calbindin 28K
(CALB; Sigma-Aldrich, St. Louis, MO), a 28-KDa protein highly
expressed by striatal medium spiny neurons. Immunoreactivity
was visualized using the diaminobenzidine (DAB)–immunoperox-
idase technique as previously described [52]. To measure the area
of medium spiny striatal neurons, images were captured from
three 1.0-mm-square confocal microscope fields, in each of three
spaced coronal sections in each hemisphere of 6 mice from each
group. Area of CALB immunoreactivity was calculated using Zeiss
LSM software for approximately 400 neurons per animal. The
average area of striatal neurons in each animal, and then in each
group, was calculated.
Evaluation of neuronal intranuclear inclusions (NIIs)
Sections counterstained with Nissl were stained with an
antibody, EM48 (MAB5374, Chemicon, Temecula, CA) against
the mutant huntingtin protein [55]. Immunoreactivity was
visualized using the diaminobenzidine (DAB)–immunoperoxidase
technique as previously described [52]. Neurons were examined
for the presence of an NII (DAB staining) throughout the entire
depth of the neuronal nucleus. A sample of approximately 250
neurons per hemisphere in each of 6 mice per treatment group
was analyzed and the percentage of striatal neurons containing
NIIs was calculated.
Microglial morphology
Microglial were immunolabeled with mouse anti-CD-11b (AbD
Serotec MorphoSys US Inc, Raleigh, NC) and detected with the
diaminobenzidine–immunoperoxidase technique, as previously
described [52].
Phosphorylated CREB in the surviving striatal neurons
Double label immunofluorescence was employed to identify the
intensity of phosphorylated CREB (pCREB) in the striatal spiny
projection neurons [53]. The intensity of pCREB staining was
calculated in each of three 1.0-mm-square confocal microscope
fields, in each of three rostrocaudally spaced sections on each
hemisphere from 6 mice from each saline, TP10 treated R6/2
mice and wild type littermates.
Phosphorylated CREB in cortical neurons
Dual label immunofluorescence was also employed to quantify
the intensity of pCREB in cortical neurons according to the
previously described procedure [26]. Cortical neurons were
labeled for the expression of NeuN as described above.
Striatal level of Brain Derived Neurotrophic Factor (BDNF)
Striatal medium spiny neurons were identified by immunolabel-
ing for CALB as described above. Double label immunofluores-
cence was employed using an antibody against BDNF (anti-mouse
BDNF, Immunological Sciences, Italy) using a previously
described immunohistochemical protocol [54]. To evaluate the
intensity BDNF immunolabeling per medium spiny neuron, the
intensity of fluorescent BDNF immunolabeling in each of three
1.0-mm-square confocal microscope fields was first determined in
each of three rostrocaudally spaced sections on each hemisphere of
6 mice from each saline, TP10 treated R6/2 mice and wild type
littermates. The intensity of BDNF immunoreactivity per field,
expressed in arbitrary units, was calculated by Zeiss LSM software
and a mean value was obtained. BDNF immunoreactivity that was
not contained in CALB immunoreactive (i.e., interneurons)
neurons was calculated.
Statistical analyses
Survival data were analyzed by means of the product limit
method of Kaplan and Meier [56], with p value ,0.0001
considered statistically significant. For the behavioral studies and
immunohistochemical and neuropathological assessments AN-
OVA was performed included the factors of genotype, age, and
treatment as warranted. All post hoc analyses used the HSD
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significant. In the text, group means are presented 6 the standard
error of the mean. Details of the statistical analyses are presented
in the figure legends.
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